Market closed

Longboard Pharmaceuticals/$LBPH

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Longboard Pharmaceuticals

Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.

Ticker

$LBPH
Trading on

Industry

Pharmaceuticals

Employees

50

LBPH Metrics

BasicAdvanced
$2.3B
Market cap
-
P/E ratio
-$2.23
EPS
1.09
Beta
-
Dividend rate
$2.3B
1.09
$59.77
$3.60
2.8M
15.967
15.717
1.26
1.357
-30.72%
-46.66%
8.47
8.47
-31.069
-7.73%
-5.30%

What the Analysts think about LBPH

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Longboard Pharmaceuticals stock.

LBPH Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

LBPH Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $LBPH

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Longboard Pharmaceuticals stock?

Longboard Pharmaceuticals (LBPH) has a market cap of $2.3B as of November 14, 2024.

What is the P/E ratio for Longboard Pharmaceuticals stock?

The price to earnings (P/E) ratio for Longboard Pharmaceuticals (LBPH) stock is 0 as of November 14, 2024.

Does Longboard Pharmaceuticals stock pay dividends?

No, Longboard Pharmaceuticals (LBPH) stock does not pay dividends to its shareholders as of November 14, 2024.

When is the next Longboard Pharmaceuticals dividend payment date?

Longboard Pharmaceuticals (LBPH) stock does not pay dividends to its shareholders.

What is the beta indicator for Longboard Pharmaceuticals?

Longboard Pharmaceuticals (LBPH) has a beta rating of 1.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.